Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodie... Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Show more
PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.04 | -1.66666666667 | 2.4 | 2.58 | 2.32 | 494223 | 2.451796 | CS |
4 | 0.11 | 4.88888888889 | 2.25 | 2.58 | 2.06 | 327874 | 2.31475518 | CS |
12 | 0.29 | 14.0096618357 | 2.07 | 2.81 | 2 | 391904 | 2.35975002 | CS |
26 | 0.43 | 22.2797927461 | 1.93 | 2.81 | 1.38 | 376867 | 2.06764259 | CS |
52 | 0.73 | 44.7852760736 | 1.63 | 3.62 | 1.3 | 508924 | 2.11118573 | CS |
156 | -32.34 | -93.1988472622 | 34.7 | 46.4 | 1.3 | 537460 | 13.37181663 | CS |
260 | -21.24 | -90 | 23.6 | 53.762 | 1.3 | 632568 | 21.07491209 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.